{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 11 of 51', 'Study ID RCB: 2020-A00652-37', 'they can identify. PSO-TARGET is an exploratory observational, non-interventional study', \"aiming to evaluate a novel approach of assessing psoriasis patients' satisfaction towards their\", 'biologic treatment from a quality of life standpoint by using a psoriasis-specific Quality of Life', 'assessment grid.', 'Research question and objectives', 'The aim of this exploratory study is to evaluate the sensitivity and specifity of the PSO-', 'TARGET QoL Component grid as part of a new approach for assessing the level of achievement', \"of the psoriasis patient's therapeutic goal, identified by himself, after a treatment with\", 'Kyntheum This tool will be, if validated, used by physicians to devise a \"Treat to patient', 'satisfaction target\" strategy that better suits their patients\\' expectations.', \"To construct this new questionnaire, the first step was to collect psoriasis patients'\", 'feedback on what is the aspect of their life that is the most impacted by the disease and which', 'is the one they would want to improve the most. To this aim, a retrospective survey based on', 'the recollection and experience from three clinical dermatologists (two French and one', \"Belgian) of patient's expectations, has been conducted. The results of the survey have been\", 'used to analyse the type of expectations provided by the patients. Based on that analysis, the', 'expert dermatologists generated a grid containing 12 therapeutic goals equally distributed into', 'the four major psychometric components classically used in quality of life studies in patients', 'with chronic diseases (physical, subjective, relational/social and therapeutic). The proposed', 'verbatim was then reviewed by a psychologist to ensure that there was a balance between the', 'proposals; i.e. the vocabulary used was neutral enough not to guide the choices. This first step', 'has therefore given rise to a QoL component grid that will be administered to the patients', 'prior to the initiation of a systemic treatment (Kyntheum / brodalumab) to set up a main', 'objective for the upcoming treatment. At 12-16 weeks the patient will be asked to rate his/her', 'level of satisfaction in regard to the treatment objective defined prior to treatment initiation', 'using a four-point Likert scale (\"very satisfied\", \"satisfied\", \"unsatisfied\", \"very unsatisfied\"). In', 'order to evaluate the sensitivity and specificity of, the PSO-TARGET QoL component grid, the', 'patient will be asked to fill in, prior the treatment introduction and during the follow up visits,', 'the DLQI questionnaire. The primary objective of the study will be to estimate the level of', 'concordance of this satisfaction level based on the PSO-TARGET QOL tool and the reference', 'method in Quality of Life for psoriasis patients; i.e. the DLQI, at the same time point. This aim', 'will be reached by comparing, at 12-16 weeks, the DLQI and the satisfaction level given by', 'patients in regard to their own treatment objective defined at baseline using the PSO-TARGET', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 12 of 51', 'Study ID RCB: 2020-A00652-37', 'QoL component grid. True Positive (TP), False Positive (FP), True Negative (TN) and False', 'Negative (FN) will be defined using a contingency table. These quantitative variables will be', 'used to calculate the sensitivity (proportion of actual satisfied patients that are correctly', 'identified as such) and specificity (proportion of actual unsatisfied patients that are correctly', 'identified as such) of the PSO-TARGET QoL Component grid, compared to the quality of life', 'given by the DLQI. If these metrics reach a certain threshold (85%), the PSO-TARGET QoL', 'component grid will be considered for additional studies in order to validate it at a larger scale', \"and further demonstrate it is as much sound in assessing the patients' quality of life as the\", 'DLQI.', 'Because of the fact that alexithymia is highly prevalent in psoriasis patients, the grid will', 'be administered to the patient after he/she had spontaneously expressed his/her treatment', 'expectations. This should help the patient to narrow down the specific goal where his/her', 'expectation belongs. In addition, as part of a secondary objective the treating physician will', \"also choose an item from the table based on what he/she perceives in terms of patient's\", 'expectations without disclosing it to the patient. This will allow us to evaluate the level of', 'accordance between the physician-chosen and the patient-chosen therapeutic goal. As', 'another secondary endpoint, the level of achievement of the therapeutic goal will be assessed', 'at 12/16 weeks and followed-up for 52 + 4 weeks. Patients scoring the treatment as \"satisfied', 'or very satisfied\" will be considered as having achieved their therapeutic goal. Another', 'endpoint of interest (secondary) will be to assess, after 12/16 weeks of treatment, if the', 'patient chooses a new therapeutic goal, different from the one he initially defined.', 'It is important to note that, this study being observational, none of the visits (baseline', \"and follow-ups) are specific to the trial but part of the dermatologists' standard of care in both\", 'countries (France and Belgium). In addition, in order to limit variability in terms of treatment', 'profiles (dosage and administration schedule) and thus to keep the study population as', 'homogenous as possible, it has been decided to include only patients treated by Kyntheum', 'in', 'other terms Kyntheum treatment is an accessory to the study but PSO-TARGET will not', 'assess Kyntheum R efficacy per se.', 'The study objectives are the following:', 'Primary objective:', 'Assess at week 12/16, post biologic treatment, the sensitivity and the specificity, compared to', 'DLQI as a standard tool, of the PSO-TARGET QoL component grid as a novel approach aiming', \"to evaluate the patients' satisfaction with regard of their treatment.\", 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 13 of 51', 'Study ID RCB: 2020-A00652-37', 'Secondary objectives:', '-', 'Evaluate at week 12/16, post Kyntheum treatment, the percentage of patients who has', 'achieved the main treatment goal they identified in the QoL component grid at baseline.', '-', 'Identification of predictive factors (among baseline characteristics) of the achievement', 'of the main treatment goal;', '-', 'Evaluate the level of agreement between the dimensions reported by the patient and by', 'the treating physician;', '-', 'Evaluate at 52 weeks the percentage of patients for whom the therapeutic objective', 'initially achieved at the 1st follow-up visit is still maintained;', '-', 'Evaluate the percentage of patients who change their therapeutic objective after 12/16', 'weeks of treatment;', '-', 'Follow the evolution of the PASI score (at 12/16 and 52 weeks);', '-', 'Level of accordance between PASI 90/100 and the satisfaction level in regard to the', 'therapeutic objective set by the PSO-TARGET QoL Component grid;', '-', 'Follow the evolution of the DLQI score (at 12/16 and 52 weeks).', 'Study design', 'PSO-TARGET is an observational, non-interventional, prospective, multicentric,', \"international, European study requiring no change in the patients' standard of care (RIPH3 in\", 'France).', 'Population', 'Adult patients suffering from moderate to severe psoriasis vulgaris for whom the', 'dermatologist decided to prescribe a treatment with Kyntheum', 'Variables', 'Primary endpoint', '-', 'At 12/16 weeks, level of concordance between the satisfaction level in regard to the', 'therapeutic objective set by the PSO-TARGET QoL Component grid and the DLQI in', \"assessing the impact of the treatment on the patients' quality of life.\", 'Secondary endpoints', '-', 'At week 12/16, post Kyntheum treatment, the percentage of patients who achieved the', 'main treatment goal identified by the patient himself in the QoL component grid at', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']", "completion": ""}